Biogen | BIIB - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.67B 140M 2026-06
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
Amgen USD 34.96B 3.49B 2026-06
Bayer EUR 33.64B 1.66B 2026-06
Biogen USD 7.58B 278.7M 2026-09
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Eli Lilly USD 65.26B 591M 2026-09
Gilead Sciences USD 16.55B 4.02B 2026-09
Incyte USD 5.52B 505.2M 2026-09
Merck USD 36.68B 1.66B 2026-06
Moderna USD 5.82B 45M 2026-06
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Novartis USD 27.35B 744M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
PTC Therapeutics USD 2.54B 79.58M 2026-09
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 31.52B 1.36B 2026-06
Sanofi EUR 30.16B 789M 2026-03
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
Teva Pharmaceutical Industries USD 13.76B 50M 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
United Therapeutics USD 3.48B 611.7M 2026-06
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06